News Focus
News Focus
Followers 84
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: biopharm post# 172713

Tuesday, 09/02/2014 11:23:13 PM

Tuesday, September 02, 2014 11:23:13 PM

Post# of 347009

but I'm sitting here tossing the basketball around and walking over to find a magnet buried under some dirt and what do I think? you have it... thinking of PS ! lol

more than a few articles I come across mentioning that PS is "negatively" charged...



I don't have to rehash all the "Think Big, Think Bavi.." posts, or the Magnetic field of the sun flipping, or the Bavi crops or Biofuels- both from targeting flipped PS in plants to targeting flipped PS on stressed cells, hundreds of auto-immune diseases to cancer..to manufacturing advanced plastics.. NASA ..etc.. etc..etc.. but it all comes down to Physics, does it not? I believe its pure physics in how Peregrine and possibly governments are finding out truly how big targeting flipped PS really will become.

Well I'm glad to finally find a reputable profile on linked that is studying exactly this and where do they end up working? You have it.. Genentech! Now, this is what should give each and every one of you the hope, the real hope, that one day..... a swarm of BP's or ANY OTHER INDUSTRY THAT CAN UTILIZE TARGETING PS may just one day start, publicly beating down the doors of Tustin in buyout offers.

Of course... thats if Tustin even wants to consider buyout offers and I say they should tell them all to f off, ever since some have tried bury this Tustin company.

So back to that reputable profile, and some simply don't have all the tools, or information or intelligent people surrounding them till they are in the door... Genentech being one of those places that knows very well the power of PS Targeting that will influence a vast amount of innovation globally, and helping hundreds of auto-immune diseases to cancer is just the beginning.

Process Development Engineering Intern
Genentech
May 2014 – Present (5 months)South San Francisco, California
University of Colorado Boulder (Department of Physics)
Assisstant Lab Coordinator (Physics 1140)
University of Colorado Boulder (Department of Physics)
January 2013 – Present (1 year 9 months)Boulder, CO

Designing and updating lab equipment for use in the undergraduate teaching lab, especially utilizing circuit and PCB design skills. Expanding the breadth of the freshman course by writing new and updating old labs. Transitioning the course from use of MathCad to Wolfram Mathematica. Assisting students taking the course during lab sessions.
University of Colorado Boulder (Falke Lab)
Undergraduate Research Assistant
University of Colorado Boulder (Falke Lab)
June 2011 – February 2013 (1 year 9 months)Boulder, CO

Studying chemotaxis proteins in e. Coli through site-directed cysteine modification and labeling using one-sample FRET techniques, electron paramagnetic resonance (EPR), and Dexter quenching detection methods. Proteins were purified in vitro and reconstituted in membrane-bound complexes.

In a separate project, determining the docking geometry of macrophage signalling protein GRP1 on several membrane compositions to determine the role of phosphatidylserine in binding through EPR power saturation experiments.

http://www.linkedin.com/pub/duncan-chadly/53/2a5/2b6



-----------------------------------

just as PS Targeting will pick up steam in treating cancer patients.... it will pick up steam in many more places.

http://epr.muohio.edu/experiments/cw-experiments/70-power-saturation

http://web.mit.edu/speclab/www/PDF/DCIF-EPR-training-n03.pdf

I've always had that gut feeling that, ever since:

1) I started reading about flipped PS having that negative charge

2) the changes that occur with MDSC's..etc by just targeting flipped PS and allowing that maximum immune response

3) flipped PS existing in plants, animals, humans...

4) the bio-fuel processes by extraction from plants and now... PS Targeting could allow for a big change there

5) the list is too big...but Fargo should have opened the eyes of many, to see why the risk, possibly HAD to be taken.


"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y